Lithium-Carbonate as a Protectant Against Chemotherapy-Induced Myelosuppression
Rosenthal, Robert Charles
This item is only available for download by members of the University of Illinois community. Students, faculty, and staff at the U of I may log in with your NetID and password to view the item. If you are trying to access an Illinois-restricted dissertation or thesis, you can request a copy through your library's Inter-Library Loan office or purchase a copy directly from ProQuest.
Permalink
https://hdl.handle.net/2142/71324
Description
Title
Lithium-Carbonate as a Protectant Against Chemotherapy-Induced Myelosuppression
Author(s)
Rosenthal, Robert Charles
Issue Date
1985
Department of Study
Veterinary Medical Science
Discipline
Veterinary Medical Science
Degree Granting Institution
University of Illinois at Urbana-Champaign
Degree Name
Ph.D.
Degree Level
Dissertation
Keyword(s)
Health Sciences, Pharmacology
Biology, Veterinary Science
Abstract
Lithium carbonate has been used as an adjunct to cancer chemotherapy to lessen the dose-limiting myelosuppressive effects of several anti-cancer drugs. Its mechanism is unknown, but several possible sites of action have been considered. Lithium causes a neutrophilia and may protect the bone marrow against the toxic effects of myelosuppressive drugs.
The present study first investigated the pharmacokinetics of lithium in normal dogs in a crossover study of eight dogs. An iterative least squares computation was used to determine a dosage schedule based on the plasma lithium concentrations obtained. A dose of 12.24 mg/kg q 12 h was calculated to maintain serum lithium concentrations of 0.8 to 1.5 mEq/L in normal dogs. This dose was within the range previously used in other canine experiments but failed to maintain serum lithium concentrations between 0.8 and 1.5 mEq/L in this study.
In a second set of experiments, twenty-four dogs were used to evaluate the efficacy of lithium carbonate in preventing chemotherapy-induced myelosuppression. Vinblastine sulfate and nitrogen mustard were used as myelosuppressive agents in separate trials. In each trial, half the dogs received lithium carbonate for six days prior to treatment with the myelosuppressive drug. Changes in the hemogram were followed daily throughout the course of the study. Numbers of bone marrow progenitor cells and the quantity of colony-stimulating activity were measured by assaying the numbers of progenitor cell colonies grown in a semi-solid agar culture system. Statistical evaluation indicated: (1) Lithium carbonate did cause a transient neutrophilia. (2) But lithium carbonate was not effective in preventing myelosuppression. There also appeared to be a lethal interaction between lithium and nitrogen mustard as administered in this study. Some of the results conflict with those of other experiments in dogs and clinical trials in people. The conflicts indicate a need for further work to clarify both the mechanism of action of lithium and its role in the clinic.
Use this login method if you
don't
have an
@illinois.edu
email address.
(Oops, I do have one)
IDEALS migrated to a new platform on June 23, 2022. If you created
your account prior to this date, you will have to reset your password
using the forgot-password link below.
